Overview

Platelet Inhibition in Patients With Systolic Heart Failure

Status:
Completed
Trial end date:
2015-12-28
Target enrollment:
Participant gender:
Summary
The investigators aim to determine if patients with systolic heart failure treated with prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.
Phase:
Phase 4
Details
Lead Sponsor:
University of Nebraska
Collaborators:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Eli Lilly and Company
Treatments:
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine